cynala therapeutics

ASX ANNOUNCEMENT

31 August 2018

Cynata to Present at the 20th Annual Rodman & Renshaw Global Investment Conference in New York City

Melbourne, Australia; 31 August 2018: Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX: CYP) announced today that Dr Ross Macdonald, Managing Director and CEO, will present a company overview at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, on Thursday, September 6, at 12:05 p.m. EDT at the St. Regis New York in New York City.

Dr Macdonald will provide an update on Cynata and its unique Cymerus[™] therapeutic mesenchymal stem cell (MSC) technology platform, with a particular emphasis on the positive results of the Phase 1 clinical trial of its lead therapy CYP-001 for the treatment of graft-versus-host disease (GvHD).

Cynata will also participate in one-on-one meetings with U.S. and international investors and potential partners who are registered to attend. Over 2,000 institutional and other investors are expected to attend the conference, each with a significant interest in the life sciences sector.

For additional information on the conference, please visit rodmanevents.com.

Ends

CONTACTS:Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119343, ross.macdonald@cynata.comAlex Liddington-Cox, Australia Media Contact, +61 (0)474701469, alex.liddingtoncox@mcpartners.comLaura Bagby, U.S. Media Contact, 312-448-8098, blogby@6degreespr.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus[™], originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus technology addresses a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus utilises induced pluripotent stem cells (iPSCs) to produce a particular type of MSC precursor, called a mesenchymoangioblast (MCA). Cymerus provides a source of MSCs that is independent of donor limitations and an "off-the-shelf" stem cell platform for therapeutic product use, with a pharmaceutical product business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics, and provides both a unique differentiator and an important competitive position.



A Next Generation Stem Cell Therapeutics Company

Investor Presentation: Cynata Therapeutics Limited

September 2018



Important Information

This presentation has been prepared by Cynata Therapeutics Limited. ("Cynata" or the "Company") based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision.

This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Cynata Therapeutics, nor does it constitute financial product advice or take into account any individual's investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of Cynata Therapeutics and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Cynata Therapeutics is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of Cynata Therapeutics securities.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Cynata Therapeutics, its officers, directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it.

The information presented in this presentation is subject to change without notice and Cynata Therapeutics does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation.

The distribution of this presentation may be restricted by law and you should observe any such restrictions.

Forward looking statements

This presentation contains certain forward looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Cynata to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the political and economic environment in which Cynata will operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. To the full extent permitted by law, Cynata and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).



Company profile

Cynata Therapeutics is an Australian stock exchange listed clinical-stage biotechnology company developing disruptive regenerative medicines.

Financial information

Share price (27-Aug-18)	A\$1.35	
52 week low / high	A\$0.52 / A\$1.58	
Shares on issue ¹	95.7m	
Market capitalisation	A\$129m (~US\$94m)	
Cash (as at 30-June-18)	A\$12.2m	
Debt (as at 30-June-18)	-	
Enterprise value	A\$117m	


(A $1 \approx US$ \$0.73)

Source: IRESS

Notes:

- 1. Excludes 11.1m unquoted options with exercise prices ranging from \$0.40 to \$1.50 and expiry dates between 27-Sep-2018 and 4-Aug-2020 (1m subject to vesting conditions)
- 2. Represents shareholding if all options held by the Board and Management (total of 7.8m) are exercised

Share price performance (last 12 months, A\$)



Top shareholders

Shareholder				
Fidelity International	10.0%			
Fujifilm Corporation	8.5%			
Board and Management	1.1%			
Board and Management (fully diluted) ²	8.6%			




CYMERUS ANIMATION



Scalable, globally applicable technology	 Cymerus[™] platform enables production of high quality Mesenchymal Stem Cells at scale Fully patented process overcomes multiple issues with today's on-market solutions 	
Excellent results from Phase I trial in GvHD	 All trial endpoints achieved to date: no adverse safety events, highly encouraging efficacy GvHD programme well positioned to progress to Phase II Safety data enables Cynata to move directly to Phase II in other indications 	
Clear pipeline of high- potential target areas	 Cardiovascular disease identified as priority indication area for expanded trial pipeline Planning for Phase II programme in Critical Limb Ischemia (CLI) underway Compelling pre-clinical data in multiple other high-value target areas 	
Well-funded to progress clinical programme	 Cash balance of \$12.2m as at 30 June 18, reinforced by \$5.2m placement of shares to leading institutional investor Fidelity International on 30-May-18; Fidelity: #1 shareholder (~10%) 	
Attractive partnering business model	 Fujifilm hold licence option for GvHD – will pay all costs of all further development and commercialisation <u>plus</u> \$60m in milestone payments <u>plus</u> royalties if exercised Licence agreements and strategic partners for other indications being explored 	
Valuable and active market	 Estimated \$1.7bn revenue opportunity for MSC supplier for GvHD and CLI products alone Over 850 clinical trials investigating the efficacy of MSCs across numerous indications Multiple pharma companies active in stem-cell M&A 	

Cynata has the only platform in the world to produce commercial quantities of Mesenchymal Stem Cells from a single source







Cynata is nearing completion of a **successful Phase 1 clinical trial**, demonstrating **safety** and **meaningful impact on the patients' quality of life**

✓ All endpoints achieved to date

(as at Cohort B 28-day trial update, announced on 21-Jun-18)

	Cohort A (at 28 days)	Cohort A (at 100 days)	Cohort B (at 28 days)
Safety	No safety issues / adverse reactions observed		
Complete response Absence of GvHD	√ 12.5%	√ 50%	√ 57%
Partial response Improvement by at least 1 GvHD grade	√ 75%	√ 100%	√ 86%
Overall survival ¹	√ 87.5%	√ 87.5%	√ 100%

Excellent safety data allows multiple future indications to progress <u>directly</u> to Phase II


Note: prognosis for steroid unresponsive GvHD patients is typically poor, with mortality rates in excess of 90 percent².

1. One patient in cohort A died of pneumonia (unrelated to treatment) and one patient in cohort B withdrew from the trial on Day 22 www.cynata.com to commence palliative care (but remained alive as at Day 28) 2. Westin JR, Saliba RM, De Lima M, et al. Steroid-Refractory Acute GVHD: Predictors and Outcomes. Adv Hematol. 2011; 2011:601953 **Trial update** | Substantial improvement in GvHD grades observed with the majority of patients reporting a Complete Response



Cohort A, lower dose (as at 100-day readout)


Complete Response rate of 50%



Cohort B, higher dose (as at 28-day readout)

Complete Response of 57%

Cynata's goal is to produce a new generation of highly potent MSC cell therapeutics in areas of high unmet clinical need




therapeutics



Cell therapy is an active market attracting big pharma M&A interest

Cynata



 TiGenix was the first company to receive approval for an MSC therapy in Europe

founded Cynata

Cynata is executing on a clear scientific and commercial vision and continually assesses pathways to maximise shareholder value



Multiple options to create shareholder value

Build value in platform independently (e.g. continue running clinical trials)

License / partner with big Pharma to develop specific target areas (e.g. Fujifilm's existing option for GvHD)

> Asset sale (e.g. Strategic acquirer)

Fujifilm holds a licence option for development and commercialisation of Cynata's MSCs for GvHD

Exercise of Fujifilm option (US\$3m)


- Fujifilm can exercise up to 90 days after completion of Phase 1 trial.
- On exercise Cynata receive upfront US\$3m milestone payment
- Fujifilm responsible for all further development activities and costs

Phase 2 and beyond (US\$30m+ p.a.)


- Fujifilm to pay Cynata agreed milestones
 (\$60m+) and double-digit royalties on product sales
- Fujifilm's projections for the GvHD market suggest
 >US\$30m per year in royalties for Cynata



New enhanced pipeline and clear pathway to commercialisation




New Phase II programme in Critical Limb Ischemia | Opportunity Overview (ClearView Healthcare Partners)





Key upcoming milestones





- Scalable, world-first technology: Cymerus platform overcomes inherent challenges of other production methods and enables mass-production of therapeutic MSCs
- Phase II ready: Excellent Phase I results provide validation of Cynata's Cymerus platform; Cynata well positioned to progress to Phase II in GvHD and other indications
- Cardiovascular disease identified as priority indication area for clinical programme: Planning for Phase II in Critical Limb Ischemia to commence in H2 2018
- Attractive licensing-driven business model: Fujifilm licence option for GvHD worth over US\$60m plus royalties
- Valuable market opportunity: Estimated US\$1.7bn revenue opportunity for MSC supplier for GvHD and CLI products alone
- Well-funded to progress clinical programme: Cash balance of \$12.2m





Thank you for your attention

Cynata Therapeutics Limited

Level 3 62 Lygon Street Carlton Victoria 3053 Australia

Contact details:



ross.macdonald@cynata.com



+61 (0) 412 119343



www.cynata.com

